Streetbeat News

Equity Actions

APTM

Mercury Capital announced significant leadership changes at Alpha Partners Technology Merger Corp (APTM), including the resignation of CEO Matt Krna and CFO Sean O'Brien on Dec 28, 2023. Subsequently, on Jan 3, 2024, Kanishka Roy was appointed as President and CEO. Additionally, several board members resigned on Dec 28, 2023, and new members were appointed on Jan 2, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:26 pm

IMMX

Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, announced its intention to offer and sell shares of its common stock in an underwritten public offering. The offering's size and terms are yet to be disclosed and are subject to market conditions. The company plans to use the net proceeds for NXC-201 clinical trials, working capital, and general corporate purposes. Titan Partners Group, LLC is the sole book-running manager for the offering.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:21 pm

SPSC

SPS Commerce (NYSE:SPSC) has seen a decrease in short interest, with the short percent of float falling 11.78% to 3.07%. This indicates fewer shares are being shorted, suggesting a potential shift in market sentiment towards the stock. The current short interest represents 817 thousand shares, requiring approximately 6.47 days for traders to cover their short positions. This change is notable compared to the peer group average of 6.73% short interest as a percentage of float, indicating SPS Commerce has less short interest than most of its peers.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 8:15 pm

BABA

Chinese AI startup 01.AI, backed by Alibaba Group Holding Ltd. (NYSE:BABA), has raised $200 million from Alibaba Cloud and Sinovation Ventures, reaching a $1 billion valuation in eight months. Under Kai-Fu Lee's leadership, 01.AI is making strides in the AI field with its open-source model Yi, outperforming competitors on the Hugging Face leaderboard. The company aims to meet the demand for large-scale language models in China, where OpenAI and Google face restrictions.

Portfolio Pulse from Caleb Naysmith

February 05, 2024 | 7:27 pm

BMY

Bristol-Myers Squibb (NYSE:BMY) has seen significant options trading activity, indicating a bullish sentiment among big-money investors. Benzinga's options scanner revealed 35 unusual trades, with a split sentiment of 62% bullish and 38% bearish. The focus is on a price range of $40.0 to $75.0 for BMY, with notable activity in calls over puts. The company, a leader in immuno-oncology, shows a high dependence on the U.S. market. Despite a slight price drop to $48.55, indicators suggest BMY may be oversold.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 7:15 pm

LPLA

In the last three months, 4 analysts have provided diverse ratings on LPL Financial Holdings (LPLA), with a shift towards a more neutral stance in the last 30 days. The average 12-month price target has increased to $253.5, reflecting a positive outlook on the company's financial performance, including a significant revenue growth rate of 16.61% and strong profitability indicators such as an 8.89% net margin and a 10.65% ROE.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 7:00 pm

SPH

ALPS Advisors and Alerian MLP ETF have disclosed a 16.78% ownership stake in Suburban Propane Partners, according to a recent SEC 13G filing.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 6:49 pm

XOM

BofA Securities analyst Doug Leggate maintains a Buy rating on Exxon Mobil Corp (XOM) with a price target of $140, following its Q4 results. The company's Guyana project is expected to significantly contribute to free cash flow, potentially doubling it by 2027 compared to 2019. Despite a decrease in Q4 adjusted net profit and revenue, the project, along with strategic acquisitions, is anticipated to lower Exxon's post-dividend breakeven to $40 Brent by 2024. This could lead to a reset in dividend growth and share buybacks, positioning Exxon for best-in-class per share growth among peers. Leggate revised EPS estimates upwards for FY24, FY25, and FY26.

Portfolio Pulse from Lekha Gupta

February 05, 2024 | 6:06 pm

AYX

Alteryx (NYSE:AYX) received mixed analyst ratings in the latest quarter with 7 analysts providing insights. The average 12-month price target is $50.36, reflecting a 21.85% increase from the previous target of $41.33. Analyst actions varied, with some maintaining, raising, or lowering their ratings and price targets. Alteryx's financial performance shows a revenue growth of 7.91% but struggles with profitability and debt management, indicating potential challenges ahead.

Portfolio Pulse from Benzinga Insights

February 05, 2024 | 6:00 pm

FOXO

Martin Christopher Ward has reported a 17.33% ownership stake in FOXO Technologies, as disclosed in a 13D filing with the SEC.

Portfolio Pulse from Charles Gross

February 05, 2024 | 5:50 pm